NASDAQ : SCTX
Scribe Therapeutics Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 17.44 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 330.17M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Scribe Therapeutics Inc. (SCTX) reported revenue of 33.30M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 33.30M | 51.17M | 27.41M |
| Cost of Revenue | 51.05M | 60.80M | 57.08M |
| Gross Profit | -17.75M | -9.62M | -29.67M |
| Selling, General & Admin | 12.96M | 16.45M | 13.16M |
| Operating Expenses | 12.96M | 16.45M | 13.16M |
| Operating Income | -30.71M | -26.07M | -42.83M |
| Interest Expense | -2.07M | -2.39M | -2.38M |
| Interest & Investment Income | 2.28M | 3.33M | 6.15M |
| EBT Excluding Unusual Items | -30.50M | -25.14M | -39.06M |
| Other Unusual Items | -2.14M | 1.53M | 1.50M |
| Pretax Income | -32.64M | -23.61M | -37.56M |
| Income Tax Expense | -334.00K | -1.80M | 10.22M |
| Net Income | -32.30M | -21.81M | -47.79M |
| Net Income to Common | -32.30M | -21.81M | -47.79M |
| Shares Outstanding (Basic) | 2.45M | 2.43M | 2.40M |
| Shares Outstanding (Diluted) | 2.45M | 2.43M | 2.40M |
| EPS (Basic) | -13.18 | -8.98 | -19.94 |
| EPS (Diluted) | -13.18 | -8.98 | -19.94 |
| Free Cash Flow | -38.22M | -46.48M | -46.58M |
| Free Cash Flow Per Share | -15.59 | -19.14 | -19.44 |
| Gross Margin | -53.29% | -18.80% | -108.22% |
| Operating Margin | -92.20% | -50.94% | -156.24% |
| Profit Margin | -97.00% | -42.61% | -174.32% |
| Free Cash Flow Margin | -114.77% | -90.83% | -169.93% |
| EBITDA | -27.82M | -22.99M | -39.94M |
| EBITDA Margin | -83.54% | -44.93% | -145.70% |
| D&A For EBITDA | 2.89M | 3.08M | 2.89M |
| EBIT | -30.71M | -26.07M | -42.83M |
| EBIT Margin | -92.20% | -50.94% | -156.24% |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 35.59M | 12.80M | 12.60M |
| Short-Term Investments | 7.42M | 45.17M | 92.57M |
| Cash & Short-Term Investments | 43.01M | 57.96M | 105.17M |
| Accounts Receivable | 1.11M | 7.09M | 3.12M |
| Other Receivables | 124.00K | 258.00K | 398.00K |
| Receivables | 1.23M | 7.35M | 3.52M |
| Prepaid Expenses | 865.00K | 1.62M | 1.69M |
| Total Current Assets | 45.10M | 66.93M | 110.37M |
| Property, Plant & Equipment | 8.54M | 10.07M | 13.18M |
| Long-Term Deferred Charges | 500.00K | 3.60M | |
| Other Long-Term Assets | 4.29M | 713.00K | 820.00K |
| Total Assets | 57.93M | 78.22M | 127.97M |
| Accounts Payable | 2.77M | 4.57M | 3.79M |
| Accrued Expenses | 7.40M | 6.71M | 5.98M |
| Current Portion of Long-Term Debt | 37.80M | 35.34M | |
| Current Portion of Leases | 1.37M | 1.28M | 1.12M |
| Current Income Taxes Payable | 87.00K | 638.00K | |
| Current Unearned Revenue | 27.48M | 21.09M | 23.41M |
| Other Current Liabilities | 1.79M | 66.00K | 87.00K |
| Total Current Liabilities | 78.70M | 69.06M | 35.02M |
| Long-Term Debt | 34.47M | ||
| Long-Term Leases | 4.10M | 4.80M | 6.09M |
| Long-Term Unearned Revenue | 11.70M | 19.94M | 49.01M |
| Other Long-Term Liabilities | 7.92M | 7.49M | 8.88M |
| Total Liabilities | 102.42M | 101.28M | 133.47M |
| Common Stock | 14.00K | 14.00K | 14.00K |
| Additional Paid-In Capital | 16.67M | 14.24M | 9.95M |
| Retained Earnings | -181.53M | -157.71M | -135.90M |
| Comprehensive Income & Other | -2.00K | 35.00K | 72.00K |
| Total Common Equity | -164.85M | -143.42M | -125.86M |
| Shareholders' Equity | -44.49M | -23.06M | -5.50M |
| Total Liabilities & Equity | 57.93M | 78.22M | 127.97M |
| Total Debt | 43.27M | 41.43M | 41.68M |
| Net Cash (Debt) | -261.00K | 16.54M | 63.49M |
| Net Cash Per Share | -0.11 | 6.81 | 26.50 |
| Filing Date Shares Outstanding | 18.93M | 2.45M | 2.42M |
| Total Common Shares Outstanding | 2.49M | 2.45M | 2.42M |
| Working Capital | -33.59M | -2.12M | 75.36M |
| Book Value Per Share | -66.33 | -58.51 | -52.06 |
| Tangible Book Value | -164.85M | -143.42M | -125.86M |
| Tangible Book Value Per Share | -66.33 | -58.51 | -52.06 |
| Machinery | 13.00M | 12.81M | 12.39M |
| Leasehold Improvements | 4.94M | 4.94M | 4.94M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -32.30M | -21.81M | -47.79M |
| Depreciation & Amortization | 2.94M | 3.08M | 2.89M |
| Other Amortization | -2.00K | 3.58M | |
| Loss (Gain) From Sale of Assets | 5.00K | 6.00K | 122.00K |
| Loss (Gain) From Sale of Investments | 566.00K | 830.00K | 631.00K |
| Stock-Based Compensation | 4.99M | 4.14M | 2.85M |
| Other Operating Activities | 8.53M | 1.35M | 1.28M |
| Change in Accounts Receivable | 1.72M | -3.98M | -1.47M |
| Change in Accounts Payable | -1.78M | 1.55M | -1.92M |
| Change in Unearned Revenue | -21.36M | -31.39M | -6.78M |
| Change in Other Net Operating Assets | -1.15M | -2.57M | 4.94M |
| Operating Cash Flow | -37.85M | -45.21M | -45.23M |
| Capital Expenditures | -368.00K | -1.27M | -1.35M |
| Investment in Securities | 59.52M | 46.54M | 14.36M |
| Investing Cash Flow | 59.16M | 45.27M | 13.01M |
| Issuance of Common Stock | 329.00K | 142.00K | 468.00K |
| Other Financing Activities | -2.03M | -690.00K | |
| Financing Cash Flow | -1.70M | 142.00K | -222.00K |
| Net Cash Flow | 19.61M | 194.00K | -32.44M |
| Free Cash Flow | -38.22M | -46.48M | -46.58M |
| Free Cash Flow Margin | -114.77% | -90.83% | -169.93% |
| Free Cash Flow Per Share | -15.59 | -19.14 | -19.44 |
| Levered Free Cash Flow | -13.50M | ||
| Unlevered Free Cash Flow | -12.00M | ||
| Cash Income Tax Paid | 208.00K | 208.00K | 1.98M |
| Change in Working Capital | -22.58M | -36.39M | -5.22M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 291.93M | ||
| Enterprise Value | 292.19M | ||
| Debt / Equity Ratio | -0.97 | -1.80 | -7.57 |
| Net Debt / Equity Ratio | -0.01 | 0.72 | 11.54 |
| Net Debt / EBITDA Ratio | -0.01 | 0.72 | 1.59 |
| Net Debt / FCF Ratio | -0.01 | 0.36 | 1.36 |
| Asset Turnover | 0.50 | ||
| Quick Ratio | 0.56 | 0.95 | 3.10 |
| Current Ratio | 0.57 | 0.97 | 3.15 |
| Return on Assets (ROA) | -15.80% | ||
| Return on Capital Employed (ROCE) | 147.80% | -284.50% | -46.10% |
| Buyback Yield / Dilution | -1.39% |